H1 2023 financials included the following statement in relation to royalties etc and was not apparent in todays detail as far is I could ascertain.It is simplistic but clear:
Potential milestone payments and royalties payable to Neuren for NNZ-2591 in Rett and Fragile X are identical to trofinetide milestone payments and royalties in each of the North American and other regions.Neuren retains the worldwide rights to NNZ-2591 in all other indications.
Kens
Ann: H1 2024 financial results, page-14
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.27 |
Change
-0.070(0.57%) |
Mkt cap ! $1.568B | |||
| Open | High | Low | Value | Volume |
| $12.30 | $12.40 | $12.16 | $2.116M | 172.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1925 | $12.26 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.36 | 1035 | 1 |
View Market Depth
| Last trade - 16.10pm 05/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |